Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivityIlirjana Bajrami, Alan Ashworth, Jessica Frankum et al.|Cancer Research|2013Cited by 367
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Aude Fléchon et al.|Nature Medicine|2021Cited by 115
LAB-PEDIATRICS LABORATORY RESEARCHDébora Reis de Carvalho, Juàn Fueyo, L. Bjerke et al.|Neuro-Oncology|2012Cited by 1